Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Neuroimmunology & Neuroinflammation
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

Share

October 2014; 1 (3) Clinical/Scientific NotesOpen Access

Avidity of vaccine-induced influenza IgG fails to increase in fingolimod-treated patients with MS

Matthias Mehling, Dominik Eichin, Patricia Hafner, Gideon Hönger, Ludwig Kappos, Christoph Hess
First published September 11, 2014, DOI: https://doi.org/10.1212/NXI.0000000000000028
Matthias Mehling
From the Immunobiology Laboratory/Department of Biomedicine and Medical Outpatient Department (M.M., D.E., G.H., C.H.) and the Department of Neurology and Clinical Neuroimmunology Laboratory/Department of Biomedicine (M.M., P.H., L.K.), University Hospital Basel, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dominik Eichin
From the Immunobiology Laboratory/Department of Biomedicine and Medical Outpatient Department (M.M., D.E., G.H., C.H.) and the Department of Neurology and Clinical Neuroimmunology Laboratory/Department of Biomedicine (M.M., P.H., L.K.), University Hospital Basel, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patricia Hafner
From the Immunobiology Laboratory/Department of Biomedicine and Medical Outpatient Department (M.M., D.E., G.H., C.H.) and the Department of Neurology and Clinical Neuroimmunology Laboratory/Department of Biomedicine (M.M., P.H., L.K.), University Hospital Basel, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gideon Hönger
From the Immunobiology Laboratory/Department of Biomedicine and Medical Outpatient Department (M.M., D.E., G.H., C.H.) and the Department of Neurology and Clinical Neuroimmunology Laboratory/Department of Biomedicine (M.M., P.H., L.K.), University Hospital Basel, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ludwig Kappos
From the Immunobiology Laboratory/Department of Biomedicine and Medical Outpatient Department (M.M., D.E., G.H., C.H.) and the Department of Neurology and Clinical Neuroimmunology Laboratory/Department of Biomedicine (M.M., P.H., L.K.), University Hospital Basel, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christoph Hess
From the Immunobiology Laboratory/Department of Biomedicine and Medical Outpatient Department (M.M., D.E., G.H., C.H.) and the Department of Neurology and Clinical Neuroimmunology Laboratory/Department of Biomedicine (M.M., P.H., L.K.), University Hospital Basel, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Avidity of vaccine-induced influenza IgG fails to increase in fingolimod-treated patients with MS
Matthias Mehling, Dominik Eichin, Patricia Hafner, Gideon Hönger, Ludwig Kappos, Christoph Hess
Neurol Neuroimmunol Neuroinflamm Oct 2014, 1 (3) e28; DOI: 10.1212/NXI.0000000000000028

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
804

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Fingolimod—an efficacious compound for the treatment of relapsing multiple sclerosis (MS)—functionally antagonizes the S1P receptor.1,–,3 This antagonism inhibits egress of T cells from secondary lymphoid tissues,2 affects B cell migration, and functionally affects germinal center reactions.4

Although vaccine-specific antibodies can be induced in patients with MS under fingolimod therapy,5 the magnitude of such responses is reduced.6 It is unknown whether the quality of a vaccine-specific response, reflected for example in the avidity of induced antibodies, is affected by fingolimod.

Here, in a prospective open-label study that was approved by the institutional review board, we assessed the avidity of the immunoglobulin (Ig) G response targeting influenza A and B before and after influenza vaccination. Avidity was compared between patients with MS treated with fingolimod and interferon-β (IFN-β), as well as in a group of healthy controls (HC). All study participants gave written informed consent before entering the study. Patients had to fulfill the following inclusion criteria: definite relapsing MS, treatment with fingolimod (0.5 mg/day) or with IFN-β, and age ≥18 and ≤65 years. HC had to fulfill the following inclusion criteria: absence of apparent acute or chronic disease and age ≥18 and ≤65 years. Exclusion criteria for all study participants were known hypersensitivity to influenza vaccine, influenza vaccination during the 180 days before entering the study, therapy with Igs or blood products during the 90 days before entering the study, treatment with steroids or immunomodulators (other than IFN-β or fingolimod), and pregnancy. The primary research question was assessment of a vaccine-induced increase in the avidity of anti-influenza antibodies following influenza vaccination.

Characteristics of the study population were as follows. Patients treated with fingolimod: n = 10 (6 female/4 male), mean age 44.7 years, mean disease duration 11.2 years, mean Expanded Disability Status Scale (EDSS) score 2.6, mean duration of fingolimod treatment 2.9 years. Patients treated with IFN-β: n = 10 (8 female/2 male), mean age 40.8 years, mean disease duration 5.9 years, mean EDSS score 2.0, mean duration of IFN-β treatment 3.6 years. HC: n = 15 (7 female/8 male), mean age 36.1 years. Blood samples were obtained before vaccination and 7, 14, and 28 days after vaccination (Mutagrip; Sanofi Pasteur SA, Lyon, France; year adjusted for 2009/2010).

The avidity of influenza-specific antibodies was determined by comparing binding of influenza-specific IgG in buffered saline vs binding after incubation in 6 M urea (10 minutes) using a quantitative ELISA system, as previously described (Genzyme Virotech, Ruesselsheim, Germany).5,7 Thus, obtained avidity index data were distributed normally (Shapiro–Wilk test) and statistically analyzed by 2-sided Student t test. p values <0.05 were considered statistically significant.

Prior to vaccination, avidity of IgG specific for influenza A and B was similar in all study groups (figure, A and B). Following vaccination, the avidity of IgG targeting influenza A and B significantly and similarly increased in patients treated with IFN-β and in HC (figure, A and B). In contrast, among individuals treated with fingolimod, no significant vaccine-induced increase in the avidity of influenza-specific IgG, against both type A and B, was detected (figure, A and B). Vaccination was tolerated comparably well in all study groups.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure Avidity of IgG specific for influenza A and B following flu vaccination

Avidity of immunoglobulin (Ig) G specific for influenza A and B before and after influenza vaccination in healthy controls (HC) and in patients with multiple sclerosis (MS) treated with interferon-β (IFN-β) and fingolimod. (A) Avidity index of anti-influenza A IgG before and 7, 14, and 28 days after vaccination. (B) Avidity index of anti-influenza B IgG before and 7, 14, and 28 days after vaccination. Mean data are shown; error bars indicate the standard error of the mean.

These data demonstrate that patients with MS treated with fingolimod significantly differ from HC and patients with MS treated with IFN-β in that they fail to increase avidity of influenza-specific IgG following vaccination. Our study thus captures for the first time a qualitative difference of an antibody response among individuals treated with fingolimod. This is particularly interesting because the concentration of anti-influenza antibodies induced by vaccination does not necessarily differ in patients with MS treated with fingolimod compared to HC.5 Limitations of our study are that the vaccination model we used does not reflect the complexity of a real-world infection and that our cohorts were not tightly matched for age. Also, our observation remains associative, and the study was neither powered nor intended to assess clinical endpoints in relation to avidity of vaccine-specific antibody responses. Irrespective of these limitations, however, the data firmly indicate that so-called protective antibody titers—a measure that lacks the dimension of quality—should be interpreted with extra care in patients with MS treated with fingolimod. Although antibody avidity has not been directly linked to protective immunity in humans yet, data from human antibody adoptive transfer animal models indicate that increased avidity of vaccine-induced antibodies correlates with protective immunity.8,9 Thus, our data may help to explain the increased rate of lower respiratory tract infections observed in patients with MS treated with fingolimod. Maintaining a high level of vigilance for clinically relevant infection despite vaccination thus seems indicated when caring for patients treated with fingolimod. This study provides Class III evidence that patients with MS taking fingolimod did not significantly increase the avidity of the IgG antibody response targeting influenza following influenza vaccination.

Acknowledgments

Acknowledgment: The authors thank K. Wild for excellent support with organization of study logistics.

Footnotes

  • ↵* These authors contributed equally to the manuscript.

  • Author contributions: M. Mehling, L. Kappos, and C. Hess initiated and organized the study. M. Mehling and P. Hafner organized patient-related study logistics. M. Mehling and D. Eichin performed the main experimental work. G. Hönger helped with some experimental procedures. M. Mehling and C. Hess analyzed the data and conducted statistical analysis. C. Hess supervised laboratory-related parts of the study. M. Mehling, L. Kappos, and C. Hess wrote the manuscript.

  • Study funding: This investigator-initiated and sponsored study was supported by Novartis AG, Basel, Switzerland. The sponsor was not involved in designing the study, data collection, data analysis and interpretation, or writing of the report. C. Hess is supported by the Swiss National Science Foundation (310030_153059). L. Kappos and M. Mehling are supported by the Swiss MS Society.

  • Disclosure: M. Mehling, D. Eichin, P. Hafner and G. Hönger report no disclosures. L. Kappos is on the editorial board for Multiple Sclerosis Journal, Multiple Sclerosis and Related Disorders, and Journal of Neurology; and received research support from Actelion, Addex, Bayer Health Care Pharmaceuticals, Biogen Idec, Biotica, CSL Behring, Genzyme, Lilly, Merck Serono, Mitsubishi, Novartis, Ono Pharma, Pfizer, Receptos, Roche, Sanofi-aventis, Santhera, Teva, UCB, Xenoport, the Swiss MS Society, the Swiss National Research Foundation, and the European Union. C. Hess reports no disclosures. Go to Neurology.org/nn for full disclosures. The Article Processing Charge was paid by the authors.

  • Received February 26, 2014.
  • Accepted in final form August 8, 2014.
  • © 2014 American Academy of Neurology

This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

References

  1. 1.↵
    1. Kappos L,
    2. Radue EW,
    3. O'Connor PW,
    4. et al
    . A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387–401.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Matloubian M,
    2. Lo CG,
    3. Cinamon G,
    4. et al
    . Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004;427:355–360.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Cohen JA,
    2. Barkhof F,
    3. Comi G,
    4. et al
    . Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402–415.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Zhang X,
    2. Wang G,
    3. Guan H,
    4. et al
    . FTY720 suppresses humoral immunity by inhibiting germinal center reaction. Blood 2004;104:4129–4133.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Mehling M,
    2. Hilbert P,
    3. Fritz S,
    4. et al
    . Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients. Ann Neurol 2011;69:408–413.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Kappos L,
    2. Arroyo R,
    3. Izquierdo G,
    4. et al
    . A controlled study on the effect of fingolimod (FTY720) on the immune response following seasonal influenza vaccination and tetanus toxoid booster injection in patients with multiple sclerosis. Mult Scler J 2011;17:S126.
    OpenUrl
  7. 7.↵
    1. Polack FP,
    2. Hoffman SJ,
    3. Crujeiras G,
    4. Griffin DE
    . A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat Med 2003;9:1209–1213.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Usinger WR,
    2. Lucas AH
    . Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. Infect Immun 1999;67:2366–2370.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Romero-Steiner S,
    2. Musher DM,
    3. Cetron MS,
    4. et al
    . Reduction in functional antibody activity against streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis 1999;29:281–288.
    OpenUrlAbstract/FREE Full Text

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy

Dr. Jeffrey Allen and Dr. Nicholas Purcell

► Watch

Related Articles

  • No related articles found.

Topics Discussed

  • All Immunology
  • Multiple sclerosis

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Article
    Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis
    Ludwig Kappos, Matthias Mehling, Rafael Arroyo et al.
    Neurology, January 30, 2015
  • Articles
    Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis
    M. Mehling, T.A. Johnson, J. Antel et al.
    Neurology, February 21, 2011
  • Article
    Impact of siponimod on vaccination response in a randomized, placebo-controlled study
    Mike Ufer, Kasra Shakeri-Nejad, Anne Gardin et al.
    Neurology: Neuroimmunology & Neuroinflammation, September 14, 2017
  • Research
    Uptake and Attitudes About Immunizations in People With Multiple Sclerosis
    Ruth Ann Marrie, Leanne Kosowan, Gary R. Cutter et al.
    Neurology: Clinical Practice, April 22, 2021
Neurology - Neuroimmunology Neuroinflammation: 10 (3)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Neuroimmunology & Neuroinflammation
Online ISSN: 2332-7812

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise